Lifileucel not checked

Iovance Biotherapeutics, Inc. · LN-145 · LN - 144

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
5 active
9 in total · 5 in the EU
Targets
—
None known yet

What this is

How it works
A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
How it’s given
“A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.”In the company’s words, NCT05727904 on ClinicalTrials.gov
Tested for
Metastatic Melanoma (2 trials), Unresectable Melanoma (2 trials), Melanoma, Melanoma (Skin Cancer), Endometrial Cancer, Metastatic Non Small Cell Lung Cancer, Sarcoma, Soft Tissue Sarcoma (STS) and 3 more
Main trialPhase 3
“This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.”In the company’s words, NCT05727904 on ClinicalTrials.gov
Other names
LN-145 · Tumor-Infiltrating Lymphocytes · TIL · LN - 144

Other drugs for Metastatic Melanoma

All 196 drugs for Metastatic Melanoma

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 1 Mar 2028 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Phase 2Active, not recruiting Dec 2027 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Phase 2Recruiting May 2028 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Phase 2Recruiting Dec 2030 Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Phase 2Recruiting 1 Sep 2033 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
Phase 2Completed 8 Aug 2022 Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Phase 2Completed 24 Oct 2024 Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
Phase 2Terminated 22 Aug 2025 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Phase 2Terminated 20 Feb 2026 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Lifileucel

Following is part of Solo: you see every change to Lifileucel the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in